SOPHiA GENETICS Reports Strong Q4 2025 Performance, Projects 20%-22% Growth for 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Source: PRnewswire
- Strong 2025 Performance: SOPHiA GENETICS reported significant growth in 2025, with projected revenue growth of 20%-22% for 2026, establishing a solid foundation for the company's future expansion.
- Leadership Transition: The company announced that Ross Muken will succeed Jurgi Camblong as CEO on July 1, 2026, with Camblong transitioning to Executive Chairman, ensuring continuity and stability in strategic direction.
- Market Opportunities: SOPHiA GENETICS will focus on developing its MSK-ACCESS® liquid biopsy application and seek new opportunities in the U.S. market while revitalizing its biopharma business, which is expected to further drive revenue growth.
- Strategic Investment: The company plans to enhance its global influence in the healthcare market through technological innovation and market expansion, particularly in the field of data-driven precision medicine, driving long-term growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SOPH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SOPH
Wall Street analysts forecast SOPH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SOPH is 7.00 USD with a low forecast of 7.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.170
Low
7.00
Averages
7.00
High
7.00
Current: 5.170
Low
7.00
Averages
7.00
High
7.00
About SOPH
SOPHiA GENETICS SA is a Switzerland-based company primarily engaged in the healthcare technology industry. The Company’s key product is SOPHiA DDM, which is a cloud-native software-as-a-service (SaaS) platform. The platform analyses multimodal data, including genomics, radiomics, clinical, biological, and digital pathology data, to generate actionable insights for patients with cancer or rare diseases, bringing the power of data-driven medicine to patients across the globe. Additionally, the Company aids BioPharma partners with artificial-intelligence-powered drug discovery, development, and deployment. The Company has offices in Switzerland, France, and the United States and operates worldwide.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
SOPHiA GENETICS Projects 20%-22% Revenue Growth in 2026 and Appoints New CEO
- 2025 Financial Performance: SOPHiA GENETICS anticipates a revenue growth of 20%-22% for Q4 and the full year 2025, indicating strong performance in the AI-driven precision medicine sector and laying a solid foundation for future growth.
- Management Transition: The company announced that Ross Muken will succeed Jurgi Camblong as CEO on July 1, 2026, with Camblong transitioning to Executive Chairman, ensuring continuity and stability in the company's strategic direction.
- Market Opportunities: SOPHiA GENETICS plans to leverage its leading liquid biopsy application MSK-ACCESS® and potential opportunities in the U.S. market to further drive business growth in 2026, demonstrating the company's keen insight into market demands.
- Strategic Investment: During Muken's tenure, he successfully transformed the commercial organization and accelerated sales processes, and he is expected to continue leveraging his extensive experience to enhance the company's global impact and market share.
Continue Reading
SOPHiA GENETICS Reports Strong Q4 2025 Performance, Projects 20-22% Revenue Growth for 2026
- Strong 2025 Performance: SOPHiA GENETICS reported robust Q4 results in 2025, exceeding new business booking targets and laying the groundwork for future growth, with projected revenue growth of 20-22% in 2026, highlighting the company's sustained leadership in precision medicine.
- Executive Transition Plan: The company announced that Ross Muken will succeed co-founder Jurgi Camblong as CEO on July 1, 2026, while Camblong transitions to Executive Chairman, ensuring continuity and stability in the company's strategic direction.
- Market Opportunities and Growth Catalysts: SOPHiA GENETICS aims to leverage its leading Liquid Biopsy application MSK-ACCESS® and valuable opportunities in the U.S. market to reinvigorate its BioPharma business, which is expected to significantly enhance operational leverage and financial position.
- Strategic Leadership Adjustments: Kevin Puylaert has been appointed Chief Sales Officer, tasked with driving sales growth in the EMEA region, further solidifying the company's competitive edge in the global market.
Continue Reading